Skip to main content
Clinical Trials/CTRI/2022/08/044696
CTRI/2022/08/044696
Not yet recruiting
未知

A prospective comparative evaluation of dysphagia in surgically resected oral cavity cancers treated by dysphagia optimized volumetric modulated arc therapy (Do-VMAT) versus standard volumetric modulated arc therapy (S-VMAT)

Homi Bhabha Cancer Hospital And Mahamana Pandit Madan Mohan Malaviya Cancer Centre0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C04- Malignant neoplasm of floor of mouthHealth Condition 2: C03- Malignant neoplasm of gumHealth Condition 3: C06- Malignant neoplasm of other and unspecified parts of mouthHealth Condition 4: C02- Malignant neoplasm of other and unspecified parts of tongue
Sponsor
Homi Bhabha Cancer Hospital And Mahamana Pandit Madan Mohan Malaviya Cancer Centre
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Homi Bhabha Cancer Hospital And Mahamana Pandit Madan Mohan Malaviya Cancer Centre

Eligibility Criteria

Inclusion Criteria

  • Histologically proven squamous cell carcinoma of oral cavity (excluding lip)
  • Written informed consent
  • Age \- 18 to 70 years
  • Karnofsky performance status 70 or above
  • Adequate surgical resection of primary and nodal diseas
  • Non\-metastatic disease
  • Patients planned for adjuvant chemo\-radiation only (Extra capsular extension \+ve, Margin \+ve or patients receiving NACT prior to surgery)
  • Only patients taking intake orally at the time of start of radiation will be included

Exclusion Criteria

  • 1\.Any histopathology other than SCC
  • 2\.Previous radiotherapy to the head and neck region
  • 3\.Synchronous or metachronous malignancy
  • 4\.Pregnant or lactating women
  • 5\.Uncontrolled concurrent illness like Diabetes mellitus (DM), Hypertension (HTN), tuberculosis
  • 6\.Evidence of distant metastasis
  • 7\.Recurrent or residual disease.
  • 8\.Current or previous tracheostomy placement.
  • 9\.Posterior pharyngeal wall, post cricoid and retro pharyngeal lymph node involvement
  • 10\.Patients on Ryles tube feeding at the time of RT start will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials